Page last updated: 2024-12-05
flumethiazide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 8992 |
CHEMBL ID | 2105128 |
CHEBI ID | 135404 |
SCHEMBL ID | 26534 |
MeSH ID | M0499369 |
Synonyms (62)
Synonym |
---|
trifluomethylthiazide |
148-56-1 |
2h-1,4-benzothiadiazine-7-sulfonamide, 6-(trifluoromethyl)-, 1,1-dioxide |
flumetiazid |
ademol |
nsc-44626 |
routrax |
fludemil |
flumethiazid |
nsc44626 |
trifluoromethylthiazide |
6-trifluoromethyl-7-sulfamoyl-4h-1,4-benzothiadiazine 1,1-dioxide |
4h-1,4-benzothiadiazine-7-sulfonamide, 6-(trifluoromethyl)-, 1,1-dioxide |
6-(trifluoromethyl)-1,4-benzothiadiazine-7-sulfonamide 1,1-dioxide |
flumethiazide |
7-sulfamoyl-6-trifluoromethyl-2h-1,4-benzothiadiazine 1,1-dioxide |
6-trifluoromethyl-7-sulfamyl-1,4-benzothiadiazine 1,1-dioxide |
wln: t66 bswm enj hxfff iszw |
ademil |
6-(trifluoromethyl)-1,4-benzothiadiazine-7-sulfonamido 1,1-dioxide |
4h-1,2,4-benzothiadiazine-7-sulfonamide, 6-(trifluoromethyl)-, 1,1-dioxide |
flumethiazidum [inn-latin] |
6-trifluoromethyl-7-sulfamyl-1,2,4-benzothiadiazine-1,1-dioxide |
6-(trifluoromethyl)-1,2,4-benzo-thiadiazine-7-sulfonamide 1,1-dioxide |
7-sulfamoyl-6-trifluoromethyl-2h-1,2,4-benzothiadiazine 1,1-dioxide |
6-(trifluoromethyl)-1,4,2-benzothiadiazine-7-sulfonamido 1,1-dioxide |
nsc 44626 |
flumetiazida [inn-spanish] |
flumetiazide [dcit] |
hsdb 2845 |
6-trifluoromethyl-7-sulfamoyl-4h-1,2,4-benzothiadiazine 1,1-dioxide |
flumethiazide [inn:ban] |
flumethazide |
einecs 205-717-4 |
6-trifluoromethyl-7-sulfamyl-1,2,4-benzothiadiazine 1,1-dioxide |
6-trifluoromethyl-7-sulfamoyl-4h-1,4,2-benzothiadiazine 1,1-dioxide |
6-(trifluoromethyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide |
ademol (tn) |
flumethiazide (inn) |
D02453 |
CHEBI:135404 |
2h-1,2,4-benzothiadiazine-7-sulfonamide,6-(trifluoromethyl)-, 1,1-dioxide |
trifluoromethyl thiazide |
CHEMBL2105128 |
flumethiazidum |
flumetiazide |
flumetiazida |
2h-1,2,4-benzothiadiazine-7-sulfonamide, 6-(trifluoromethyl)-, 1,1-dioxide |
3pa0cds0m5 , |
unii-3pa0cds0m5 |
SCHEMBL26534 |
flumethiazide [mi] |
flumethiazide [who-dd] |
flumethiazide [vandf] |
flumethiazide [hsdb] |
flumethiazide [inn] |
6-trifluoromethyl-7-sulfamoyl-1,2,4-benzothiadiazine-1,1-dioxide |
DTXSID60163862 |
1,1-dioxo-6-(trifluoromethyl)-4h-benzo[e][1,2,4]thiadiazine-7-sulfonamide |
1,1-dioxo-6-(trifluoromethyl)-4h-1lambda6,2,4-benzothiadiazine-7-sulfonamide |
Q27257858 |
AKOS040751820 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" No evaluation was made in the remaining patient in the series because further adjustment in dosage was required." | ( A new antihypertensive agent. Clinical evaluation of a Rauwolfia-flumethiazide combination (rautrax). NESCHE, GE, 1960) | 0.48 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
benzothiadiazine | Heterocyclic compound of a ring with sulfur and two nitrogen atoms fused to a benzene ring. Members inhibit sodium-potassium-chloride symporters and are used as diuretics. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (20)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 16 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (10.00) | 24.3611 |
2020's | 2 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 30.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.63) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |